From: JAK2 mutation may predict response and guide first line treatment in rheumatoid arthritis
 |  | Patients | Control |
---|---|---|---|
Sexa | Male | 14 (16.5%) | 13 (26%) |
Female | 71(83.5%) | 37 (74%) | |
Age years | Range | 36–65 | 33–61 |
Mean ± SD | 48.7 ± 7.2 | 42 ± 6.1 | |
ESR mm/h | Mean ± SD | 47.9 ± 17.7a | 11 ± 4 |
CRP mg/L | Mean ± SD | 33.2 ± 27.8a | 6 ± 5.2 |
TNF-alpha pg/ml | Mean ± SD | 38.4 ± 36.5a | 19.2 ± 5.4 |
IL-6 pg/ml | Mean ± SD | 66.3 ± 55.6a | 13.1 ± 2.7 |
JAK2 | Mutant | 45 (52.9%) | 0 (0%) |
Non-mutant | 40 (47.1%) | 50 (100%) |